Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Rituximab 45Cyclophosphamide 32fludarabine phosphate 28fludarabine 19ibrutinib 17Peripheral Blood Stem Cell Transplantation 17Lenalidomide 17venetoclax 13Mycophenolic Acid 10Cyclosporine 10acalabrutinib 9Whole-Body Irradiation 9Filgrastim 9obinutuzumab 7Bendamustine Hydrochloride 7Antilymphocyte Serum 7Radiotherapy 6Methotrexate 6Melphalan 6Prednisone 5Etoposide 5Busulfan 5zanubrutinib 4pirtobrutinib 4aldesleukin 4Vincristine 4Tacrolimus 4Indium 4Immunotherapy, Adoptive 4Granulocyte Colony-Stimulating Factor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Lymphocytic, Chronic, B-Cell × Deuterium Oxide × Clear all
NCT01752426 2020-02-24

Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL

M.D. Anderson Cancer Center

Phase 1/2 Completed
30 enrolled 9 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡